Brisbane, Australia, 4 October 2019 — ResApp Health Limited (ASX:RAP), a leading digital health company developing smartphone applications for the diagnosis and management of respiratory disease, is pleased to announce that it has been selected to join the Startup Creasphere Digital Health Program in Munich. Startup Creasphere, powered by Plug and Play, was established in 2018 and is the first health-focused accelerator in Munich.
“We are very excited to participate in the Startup Creasphere program to build and pilot a consumer health-focused product using our novel respiratory diagnostic algorithms,” said Tony Keating, CEO and Managing Director of ResApp. “Collaborating with the consumer healthcare business unit of Sanofi during the program provides ResApp with an outstanding opportunity to explore the direct-to-consumer market alongside global industry leaders.”
Startup Creasphere is a twelve-week program, starting this month, where ResApp will work with subject matter experts and mentors from the consumer healthcare business unit of Sanofi to explore opportunities to co-create consumer health-focused respiratory disease products. After the program neither ResApp nor Sanofi has committed to any obligations regarding any of the products created and ResApp retains all intellectual property developed under the program.
About ResApp Health Limited
ResApp Health Limited (ASX: RAP) is a leading digital health company developing smartphone applications for the diagnosis and management of respiratory disease. ResApp’s machine learning algorithms use sound to diagnose and measure the severity of respiratory conditions without the need for additional hardware. Clinical studies have demonstrated accurate diagnosis of lower respiratory tract disease, upper respiratory tract infection, pneumonia, bronchiolitis, croup, asthma exacerbation/reactive airway disease, chronic obstructive pulmonary disease, chronic obstructive pulmonary disease exacerbation and obstructive sleep apnoea. ResApp’s smartphone-based acute respiratory disease diagnostic test, ResAppDx-EU, is CE Marked in the European Union and TGA approved in Australia. Potential customers of ResApp’s products include healthcare providers in telehealth, emergency department, urgent care and primary care settings as well as humanitarian organisations in the developing world. For more information, visit www.resapphealth.com.au
ResApp Health Limited
ABN 51 094 468 318
Level 12, 100 Creek St, Brisbane, QLD 4000
© 2020 ResApp Health Limited. All rights reserved. US Patent No. 10,098,569, Australian Patent No. 2013239327, Japanese Patent No. 6,435,257 and Patents Pending. ResApp Health®, the ResApp Health logo and ResAppDx® are registered trademarks of ResApp Health Limited in the United States and other countries. ResAppDx is not available for sale in the United States.